| Literature DB >> 32582688 |
Li Zhang1, El-Mustapha Haddouti1, Kristian Welle1, Christof Burger1, Dieter C Wirtz1, Frank A Schildberg1, Koroush Kabir1.
Abstract
Aseptic loosening subsequent to periprosthetic osteolysis is the leading cause for the revision of arthroplasty failure. The biological response of macrophages to wear debris has been well established, however, the equilibrium of bone remodeling is not only dictated by osteoclastic bone resorption but also by osteoblast-mediated bone formation. Increasing evidence shows that wear debris significantly impair osteoblastic physiology and subsequent bone formation. In the present review, we update the current state of knowledge regarding the effect of biomaterial implant wear debris on osteoblasts. The interaction of osteoblasts with osteoclasts and macrophages under wear debris challenge, and potential treatment options targeting osteoblasts are also presented.Entities:
Keywords: aseptic loosening; macrophages; osteoblasts; osteoclasts; total joint arthroplasty; wear particles
Year: 2020 PMID: 32582688 PMCID: PMC7283386 DOI: 10.3389/fcell.2020.00352
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
Major pro-inflammatory mediators which are relevant to the context of orthopedic implant pathology in retrieved human periprosthetic tissue.
| Inflammatory cytokines | TNF-α | Promote RANKL and osteoclast differentiation, activation, and survival. Stimulate osteoclast activity, disrupt MMP/TIMP balance, promote bone resorption | |
| Chemokines | CXCL8 (IL-8) | Induce both local and systemic cell trafficking of monocytes/macrophages to the bone-implant interface | |
| Other mediators | iNOS | Synthesis of NO, promote osteoclastic bone resorption | |
| COX-2 | Synthesis of PGE2, promote osteoclastic bone resorption |
Most frequently used particles and their overall effect on osteoblasts.
| Metal particles | Titanium-based (pure-Titanium, TiO2, Ti-6Al-4V et al.) | Nanometer to Micrometer | 1. Particle internalization | |
| Polymeric particles | Polyethylene (UHMWPE et al.) | |||
| Ceramic particles | Al2O3 |
FIGURE 1The reaction of osteoblasts to particles and their crosstalk with osteoclasts and macrophages. Wear particles hamper osteoblast cellular function such as viability, proliferation, adhesion, migration, osteogenesis, and matrix mineralization. They also disturb RANKL/OPG balance and increase proinflammatory cytokine production in osteoblasts. Activated macrophages also up-regulate inflammatory cytokines and, together with osteoblasts, contribute to a peri-implant chronic inflammatory environment which favors osteoclastogenesis. TNFα, tumor necrosis factor α; GM-CSF, granulocyte macrophage colony-stimulating factor; PGE2, prostaglandin E2; LXA4, Lipoxin A4; IL, interleukin; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor kappa-B ligand.
FIGURE 2Signaling pathways in wear debris-activated osteoblasts. Wear particle internalization results in activation of several signaling pathways in osteoblasts. The activation of the MAPK and NF-κB signaling pathway up-regulates inflammatory cytokine and chemokine production, which favors chronic inflammation, while down-regulating collagen synthesis. MAPK activation disturbs osteoblastic RANKL/OPG balance and increases MMP production. Osteoclastogenesis is therefore increased while remodeling of the extracellular matrix deposition is inhibited. Wear particles also inhibit the WNT and BMP signaling pathway which mainly contributes to osteoblast differentiation. This ultimately results in decreased bone formation and increased bone resorption. BMP, bone morphogenetic protein; RANKL, receptor activator of nuclear factor kappa-B ligand; OPG, osteoprotegerin; ERK, extracellular signal-regulated kinase; JNK, Jun N-terminal kinase; MMPs, matrix metalloproteinases; NF-κB, nuclear factor-kappa B; Bax, BCL2-associated X protein; Bcl, B cell Leukemia/Lymphoma 2 apoptosis regulator.
Summary of drug candidates for the treatment of wear particle-associated osteolysis in animal models.
| Melatonin, icariin, ghrelin, LiCl, strontium ranelate, teriparatide | Wnt/β-catenin | Activator | Osteoblast proliferation↑, osteoblast differentiation↑, OPG/RANKL↑, osteoclastogenesis↓ | |
| Statins (e.g., simvastatin) | RhoA/ROCK | Inhibitor | Inflammatory reaction↓, new bone formation↑, osteoclastic bone resorption↓ | |
| SB203580, triptolide, AZD6244 | MAPK (ERK/p38/Jnk) | Inhibitor | Inflammatory cytokine↓, chemokine↓, collagen synthesis↑, autophagy↓, RANK↓, RANKL↓, OPG↑, NF-κB↓ | |
| 3-MA | Autophagy | Inhibitor | Osteoblasts apoptosis↓, proliferation↑, osteogenesis↑, inflammatory reaction↓, OPG/RANKL↑, osteoclastogenesis↓ | |
| Resveratrol, GYY4137 | SIRT1-NF-κB | Inhibitor | Osteoblastogenesis↑, inflammatory cytokine↓, chemokine↓, collagen synthesis↑ | |
| Resveratrol, GYY4137 | SIRT1-p53 | Inhibitor | Osteoblastic apoptosis↓ |